MMP9 and focal segmental glomerulosclerosis: According to the authors, intravenous infusion of bone marrow-derived MSCs reduced 24 h proteinuria and promoted the preservation of renal function in animals subjected to FSGS, in addition to promoting a decrease in the ratio between metallopeptidase Inhibitor 1 (TIMP1) and matrix metalloproteinase-9 (MMP9).